Carillon Tower Advisers’s Kura Oncology KURA Stock Holding History

Carillon Tower Advisers’s Portfolio KURA Stock Details KURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$18.2M	Sell	557,986 -584,478	-51%	-$20.5M	0.11%	259
2020 Q3	$35M	Sell	1,142,464 -359,753	-24%	-$7.94M	0.47%	52
2020 Q2	$24.5M	Hold	1,502,217	–	–	0.19%	160
2020 Q1	$13.5M	Hold	1,502,217	–	–	0.13%	231
2019 Q4	$20.7M	Hold	1,502,217	–	–	0.14%	251
2019 Q3	$22.8M	Hold	1,502,217	–	–	0.16%	227
2019 Q2	$29.6M	Hold	1,502,217	–	–	0.2%	181
2019 Q1	$24.9M	Hold	1,502,217	–	–	0.18%	215
2018 Q4	$21.1M	Hold	1,502,217	–	–	0.18%	209
2018 Q3	$26.3M	Buy	1,502,217 +576,221	+62%	+$11M	0.19%	192
2018 Q2	$16.9M	Buy	+925,996	New	+$15.7M	0.13%	240

Other funds holding KURA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Carillon Tower Advisers's KURA Position: Q4 2020 in Review

Carillon Tower Advisers reduced its Kura Oncology (KURA) stake by 51% in Q4 2020, selling an estimated $20.5M and leaving 557,986 shares worth $18.2M. The position accounts for 0.11% of the portfolio, ranked #259.

Carillon Tower Advisers first reported a position in KURA in Q2 2018 and has held it in 11 quarters since. The position peaked at $35M in Q3 2020. 198 funds tracked by Wall St. Rank hold KURA as of Q4 2020.

Carillon Tower Advisers held 557,986 shares of Kura Oncology worth $18.2M as of Q4 2020.
Carillon Tower Advisers sold 584,478 Kura Oncology shares in Q4 2020, an estimated $20.5M.
Kura Oncology made up 0.11% of Carillon Tower Advisers's portfolio in Q4 2020, its #259 holding.
Carillon Tower Advisers first reported a position in Kura Oncology in Q2 2018 and has held it in 11 quarters since.
Carillon Tower Advisers's Kura Oncology position peaked at $35M in Q3 2020.
198 funds tracked by Wall St. Rank held Kura Oncology as of Q4 2020.

Based on Carillon Tower Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.